NATCO Pharma released its financial presentation for the first quarter of fiscal 2027, indicating a significant 43% decrease in overall revenue compared to the same period in the previous year.
Despite the sharp contraction in top-line figures, the company's profit margins improved, reaching 30.9%. Further details regarding specific segment performances and operational drivers were outlined in the company's presentation slides.
